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Abstract Muscle glycogen synthesis is modulated by physiolog-
ically relevant changes in cell volume. We have investigated the 
possible involvement of integrin-extracellular matrix interactions 
in this process using primary cultures of rat skeletal muscle 
subject to hypo- or hyper-osmotic exposure with integrin binding 
peptide GRGDTP to disrupt integrin actions and the inactive 
analogue GRGESP as control. Osmotically induced increases 
(77%) and decreases (34%) in glycogen synthesis (D-[14CJ-
glucose incorporation into glycogen) were prevented by 
GRGDTP (but not GRGESP) without affecting glucose 
transport. Cytoskeletal disruption with cytochalasin D or 
colchicine had similar effects to GRGDTP. Osmotically induced 
modulation of muscle glycogen synthesis involves integrin-
extracellular matrix interactions and cytoskeletal elements, 
possibly as components of a cell-volume 'sensing' mechanism. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Modulation of metabolic processes in response to physio-
logically relevant changes of cell volume is now widely recog-
nised to occur in tissues such as liver and skeletal muscle. For 
example, cell swelling may be induced as an osmotic conse-
quence of increased solute uptake resulting from nutrient sup-
plementation or endocrine stimulation [1-6] and this appears 
to act as an anabolic signal stimulating processes such as 
glycogen synthesis. We have shown recently [5] that modula-
tion of glycogen synthesis in skeletal muscle by changes in cell 
volume involves a mechanism including phosphatidylinositol 
3-kinase (PI3-kinase) and p70S6 kinase and Krause et al. [7] 
reported concurrently that these two enzymes exhibit swelling-
induced activation in liver cells. 
The mechanisms involved in sensing changes of cell volume 
and in transducing this information to intracellular signalling 
pathways are poorly understood. Changes in cell volume are 
likely to alter the degree of 'stretch' imposed on the plasma 
membrane and a recent study indicates that interactions be-
tween integrins and specific extracellular matrix proteins are 
involved in sensing mechanically induced stretch of skeletal 
muscle [8]. The cytoplasmic domains of are integrins attached 
to the cytoskeleton and these linkages may be important ele-
ments in a system for cellular mechanotransduction [8-11]. 
"■Corresponding author. Fax: (44) (1382) 344514. 
E-mail: s.y.low@dundee.ac.uk 
Abbreviations: MAP kinase, mitogen-activated protein kinase; PI3-
kinase, phosphatidylinositol 3-kinase; FAK, focal adhesion kinase 
Activation of integrin-ßl (which is expressed in muscle) can 
stimulate Tyr-phosphorylation of focal adhesion kinase 
(FAK) with subsequent activation of mitogen-activated pro-
tein (MAP) and p70S6 kinases via mechanisms involving PI3-
kinase [8,12,13]. We have therefore investigated possible in-
volvement of integrins and the cytoskeleton in cell-volume-
mediated control of metabolism by assessing the effects of 
disrupting cytoskeletal elements or integrin-matrix interac-
tions on the modulation of glycogen synthesis in skeletal 
muscle by osmotically induced changes of cell volume. 
2. Materials and methods 
Skeletal muscle cells were harvested from thigh muscles of 1-day-
old neonatal rats (killed by cervical dislocation) and cultured as de-
scribed previously [6] in growth medium (25% M199, 65% DMEM) 
containing 10%o foetal calf serum. Myogenesis was promoted by re-
placement of calf serum with 10%o horse serum and 3%> chick embryo 
extract on day 5 of culture [6]. Cell culture media and sera were 
obtained from Life Technologies (Gibco BRL, Paisley, UK), radio-
tracers from NEN Research Products (Stevenage, UK) and GRGESP 
peptide from GENOSYS (Cambridge, UK). All other chemicals were 
obtained from Sigma (Poole, UK). 
All experiments were performed on 10-day-old confluent, multi-
nucleated muscle cells. The experimental medium contained (in 
mM) 60 NaCl, 4.9 KC1, 2.5 MgS04, 20 tris(hydroxy methyl)amino-
methane hydrochloride and 1 CaCl2, pH 7.4 (170 mosmol/kg). 
Sucrose was added to give the required osmolalities as outlined 
below. 
Uptake of the non-metabolisable glucose analogue 2-[3H(G)]deoxy-
D-glucose (9.25 kBq/well) into muscle was measured after 60 min 
exposure of cells at 37°C to hypo- (170 mosmol/kg), iso- (300 
mosmol/kg) or hyper- (430 mosmol/kg) osmotic medium using 
D-[l-14C]mannitol (1.9 kBq/well) as an extracellular marker. These 
osmotic manipulations are known to cause significant (and opposite) 
alterations in muscle cell volume [6]. Tracer uptake was stopped by 
rapidly removing the uptake buffer by aspiration and washing the 
cells with ice cold saline before liquid scintillation counting and pro-
tein assay as described previously [6]. 
Incorporation of D-[U-14C]glucose (37 kBq/well) into glycogen in 
muscle cells was measured over 60 min in hypo-, iso- and hyper-
osmotic media at 37°C. Termination of the reaction was as described 
for sugar uptake. Labelled glycogen was extracted from the muscle 
cells by 10% w/v trichloroacetic acid followed by 70% v/v ethanol 
precipitation [14] with assay for 14C activity as described previously 
[5]. 
Uptake of 2-deoxy-D-glucose (0.05 mM) and synthesis of glycogen 
from glucose (0.05 mM) were also measured during 60 min exposure 
of muscle cells to cytochalasin D (0.5 |0,M, to disrupt contractile mi-
crofilaments), colchicine (3 uM, to disrupt microtubules) or the integ-
rin binding peptide, GRGDTP (at 25 (tg/ml to disrupt integrin-matrix 
interactions by competitive binding to receptor sites [11]). The inactive 
peptide GRGESP (also at 25 ug/ml) was used as a control for the 
active form. Effects of these additions were assessed under hypo-, iso-
and hyper-osmotic conditions. 
Data are presented as the mean value ±S.E.M. for n cell prep-
arations; each experimental measurement in an individual prepara-
tion was carried out in triplicate using separate wells of a culture 
plate. 
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Fig. 1. Effect of cytochalasin D and colchicine on changes in incor-
poration of glucose into muscle cell glycogen induced by altering ex-
ternal osmolality. 0.05 mM [14C]glucose incorporation into muscle 
glycogen was measured during 60 min exposure to hypo-, iso- or 
hyper-osmotic media without or with cytochalasin D (0.5 uM; CYT 
D) or colchicine (3 uM; COL). Each value represents the mean 
±S.E.M. for eight preparations. Statistical significance was meas-
ured using paired i-test; *P<0.05 from iso-osmotic value for indi-
vidual treatments. 
3. Results 
Incorporation of [14C]glucose tracer into glycogen of muscle 
cells (i.e. glycogen synthesis) was altered in response to cell-
volume changes induced by aniso-osmotic exposure; glycogen 
synthesis was increased (by 77 ±25%, P<0 .01 , «=12) in 
hypo-osmotic medium and decreased (by 35 ±7%, P<0.05, 
n=\2) in hyper-osmotic medium (Fig. 1) relative to the over-
all control rate of 40.7 ± 8.5 pmol/h/mg protein observed in 
cells maintained under iso-osmotic conditions. Cytochalasin 
D and colchicine treatment abolished these observed changes 
in glycogen synthesis without affecting the control synthetic 
rate (Fig. 1) indicating that an intact cytoskeleton (i.e. includ-
ing microfilaments and microtubules) is important for cell 
volume-related control of metabolism. Glucose transporter 
activity in muscle cells was not significantly affected by these 
experimental manipulations (control values averaged 3.6 nmol 
2-deoxy-D-glucose/h/mg protein; Table 1) nor was total 
[14C]glucose tracer uptake into cells over 60 min (data not 
shown), confirming that measured changes in tracer incorpo-
ration into glycogen reflected changes in synthetic rate rather 
than in tracer delivery to the sarcoplasm [5]. 
Changes in incorporation of [14C]glucose into glycogen 
after hypo- or hyper-osmotic exposure were also blocked by 
inactivation of integrin-extracellular matrix interactions using 
the integrin binding peptide GRGDTP, but not by control 
(inactive) peptide (Fig. 2). Neither peptide had significant in-
dependent effects on basal glycogen synthetic rate (Fig. 2), 2-
deoxy-D-glucose transport (Table 1) or total glucose (data not 
shown) uptake under experimental conditions, again indicat-
ing that changes in incorporation of [14C]glucose into glyco-
gen reflected alterations in glycogen synthesis. 
Under all experimental conditions described here, wortman-
nin (a PI3-kinase inhibitor) blocked changes in glycogen syn-
thesis resulting from aniso-osmotic exposure [5] and signifi-
cantly decreased basal glycogen synthesis from glucose to 
about 40% of values in the absence of inhibitor (data not 
shown). The latter effect is largely attributable to an inhibitory 
effect of wortmannin on glucose transport (Table 1 and data 
not shown). 
4. Discussion 
The results of this study demonstrate that glycogen synthe-
sis in skeletal muscle is modulated in association with changes 
in cell volume (independently of changes in glucose uptake) by 
a mechanism which requires integrin-extracellular matrix in-
teractions and presumably, according to the result of cytocha-
lasin D and colchicine additions, an intact cytoskeleton. PI3-
kinase and p70se kinase are involved in modulation of muscle 
glycogen synthesis in response to cell-volume change [5] and it 
has recently been shown that integrin-mediated signal trans-
duction activates the p70S6 kinase signalling pathway by a 
mechanism involving PI3-kinase and FAK [12]. We therefore 
propose that integrins are directly involved in sensing and/or 
transducing changes in muscle cell volume with effects on 
cellular processes such as glycogen synthesis, a view consistent 
with recent work [11] which has shown that muscle stretch 
enhances neurotransmitter release from motor nerve terminals 
by a mechanism which is suppressed by peptides blocking 
integrin binding and also by certain integrin antibodies. Fur-
thermore, interaction between integrins and specific matrix 
proteins may be responsible for sensing mechanical stretch 
in vascular smooth muscle cells [15]. 
The ability of integrins to interact with specific extracellular 
matrix proteins whilst being attached to the cytoskeleton may 
enable these transmembrane proteins to act (possibly in com-
bination with associated proteins including paxillin, tensin, 
vinculin and talin) as a 'sensor' of mechanical stresses at the 
Table 1 
Effect of changes in external medium composition on 2 deoxy-D-glucose uptake in muscle cells 
Medium composition 0.05 mM 2-deoxy-D-glucose uptake (nmol/h/mg protein) 
Medium osmolality (mosmol/kg) 

























0.05 mM 2-[3H]deoxy-D-glucose uptake was measured after 60 min exposure to hypo-, iso- and hyper-osmotic media or to iso-osmotic medium 
without or with 100 nM wortmannin, 25 ug/ml GRGDTP (active), 25 |ig/ml GRGESP (control), 0.5 uM cytochalasin D or 3 uM colchicine. Each 
value represents the meaniS.E.M. for nine preparations. Statistical significance was measured using paired i-test; *P<0.05 from 300 mosmol/kg 
control. 
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Fig. 2. Effect of the integrin-binding peptide GRGDTP on changes 
in incorporation of glucose into muscle glycogen induced by altering 
external osmolality. 0.05 mM [14C]glucose incorporation into glyco-
gen was measured during exposure of muscle cells for 60 min to 
hypo-, iso- or hyper-osmotic media (170, 300, 430 mosmol/kg re-
spectively) with or without 25 ug/ml GRGDTP (active peptide) or 
25 |xg/ml GRGESP (control peptide). Each value represents the 
mean ± S.E.M. for eight preparations. Statistical significance was 
measured using paired /-test; * P<0.05 with respect to glycogen 
synthesis in iso-osmotic medium for treatment denoted. 
cell membrane [9,10] produced e.g. by changes in cell volume 
and/or stretch. Our previous results indicate [16,17] that PI3-
kinase may 'activate' the putative volume sensor in skeletal 
muscle and indeed PI3-kinase appears to be involved in pro-
viding 'positive feedback' to sustain active integrin in certain 
cell types [8,12,13]. An intact cytoskeleton also appears to be 
required as a component of the mechanism for signalling or 
sensing cell-volume change in skeletal muscle (and also in liver 
[18]). A mechanism including all these elements is proposed in 
the tensegrity model of cellular mechanotransduction [9,10], in 
which surface receptors (e.g. integrins) are coupled to intra-
cellular processes via physical associations with the cytoskele-
ton and changes in tension within the cytoskeletal framework 
(as induced e.g. by changes in cell volume or shape) may have 
direct involvement in processes of signal amplification and 
adaptation. 
The intracellular regulatory mechanisms which link cell 
swelling to glycogen synthase activity remain to be fully elu-
cidated. Stimulation of glycogen synthesis by cell swelling is 
likely to be due to activation of glycogen synthase (i.e. de-
phosphorylation via effects on glycogen-associated kinases 
and/or phosphatases) rather than stimulation of new protein 
synthesis, since our preliminary data (not shown) indicate that 
the cell swelling-induced stimulation of glycogen synthesis in 
muscle cells is insensitive to the protein synthesis inhibitor 
cycloheximide. Responses to both increased and decreased 
cell volume involve signal transduction pathways with simi-
larities to those associated with insulin and growth factor 
signalling (i.e. involvement of the enzymes PI3-kinase and 
p70S6 kinase), but these pathways appear to run in parallel 
because the anabolic effects of insulin and cell swelling are 
largely additive (i.e. cell swelling causes increased glycogen 
synthesis in cells already stimulated by supramaximal insulin 
concentrations [5]). Further distinctions between these path-
ways are (i) that muscle glucose transport is insensitive to 
changes in cell volume (Table 1) and (ii) that disruption of 
components of the putative integrin-dependent 'volume-sig-
nalling' pathway does not affect basal levels of glucose trans-
port in our primary muscle cultures in contrast to the effect of 
insulin-signalling pathways on muscle glucose transport [5,19]. 
Insulin may modulate the activity of FAK [20], allowing for 
feedback/feed-forward interactions between endocrine and in-
tegrin signalling mechanisms and their respective stimuli. 
It is possible that integrin-dependent signalling mechanisms 
would be triggered by mechanical stresses resulting from a 
variety of physiological and pathophysiological events which 
themselves both involve and modulate metabolism. In partic-
ular, the intracellular signalling cascades modulating the stim-
ulation of glycogen synthesis after cell volume increase appear 
to share common steps with those modulating muscle growth 
or remodelling after mechanical load [21,22], but the extent of 
possible interactions and the specific mechanisms which may 
be involved remain to be elucidated. 
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